{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:54:56Z","timestamp":1780376096934,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010447","name":"DZHK","doi-asserted-by":"crossref","award":["BER 5.4 PR"],"award-info":[{"award-number":["BER 5.4 PR"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG \u2013 KI 712\/10-1"],"award-info":[{"award-number":["DFG \u2013 KI 712\/10-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11886-023-01998-0","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:02:32Z","timestamp":1700640152000},"page":"1859-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes"],"prefix":"10.1007","volume":"25","author":[{"given":"Ulrich","family":"Kintscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"1998_CR1","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"\u2022\u2022 Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179:3220\u201334. This article provides in-depth overview over the pharmacodynamics and pharmacokinetics of all non-steroidal MRA, and discusses recent clinical data.","journal-title":"Br J Pharmacol"},{"key":"1998_CR2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0960-0760(00)00112-6","volume":"74","author":"NJ Mckenna","year":"2000","unstructured":"Mckenna NJ, O\u2019Malley BW. From ligand to response: generating diversity in nuclear receptor coregulator function. J Steroid Biochem Mol Biol. 2000;74:351\u20136.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1998_CR3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268\u201375.","journal-title":"Science"},{"issue":"822\u2013822","key":"1998_CR4","volume":"142","author":"NJ Mckenna","year":"2010","unstructured":"Mckenna NJ, O\u2019malley BW. SnapShot: nuclear receptors I. Cell. 2010;142(822\u2013822): e821.","journal-title":"Cell"},{"key":"1998_CR5","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/bph.15746","volume":"179","author":"C Grossmann","year":"2022","unstructured":"Grossmann C, Almeida-Prieto B, Nolze A, et al. Structural and molecular determinants of mineralocorticoid receptor signalling. Br J Pharmacol. 2022;179:3103\u201318.","journal-title":"Br J Pharmacol"},{"key":"1998_CR6","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/JOE-17-0060","volume":"234","author":"PJ Fuller","year":"2017","unstructured":"Fuller PJ, Yang J, Young MJ. 30 Years of the mineralocorticoid receptor: coregulators as mediators of mineralocorticoid receptor signalling diversity. J Endocrinol. 2017;234:T23\u201334.","journal-title":"J Endocrinol"},{"key":"1998_CR7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","volume":"46","author":"PJ Fuller","year":"2005","unstructured":"Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227\u201335.","journal-title":"Hypertension"},{"key":"1998_CR8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","volume":"123","author":"D Fraccarollo","year":"2011","unstructured":"Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400\u20138.","journal-title":"Circulation"},{"key":"1998_CR9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","volume":"57","author":"A Lother","year":"2011","unstructured":"Lother A, Berger S, Gilsbach R, et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011;57:746\u201354.","journal-title":"Hypertension"},{"key":"1998_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","volume":"18","author":"A Mccurley","year":"2012","unstructured":"Mccurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18:1429\u201333.","journal-title":"Nat Med"},{"key":"1998_CR11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","volume":"63","author":"AJ Rickard","year":"2014","unstructured":"Rickard AJ, Morgan J, Chrissobolis S, et al. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone\/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension. 2014;63:1033\u201340.","journal-title":"Hypertension"},{"key":"1998_CR12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","volume":"79","author":"JP Bertocchio","year":"2011","unstructured":"Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney international. 2011;79:1051\u201360.","journal-title":"Kidney international"},{"key":"1998_CR13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1161\/CIRCRESAHA.117.310985","volume":"120","author":"NR Barbaro","year":"2017","unstructured":"Barbaro NR, Kirabo A, Harrison DG. A new role of mister (MR) T in hypertension: mineralocorticoid receptor, immune system, and hypertension. Circ Res. 2017;120:1527\u20139.","journal-title":"Circ Res"},{"key":"1998_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira NS, Tostes RC, Paradis P, et al. Aldosterone, inflammation, immune system, and hypertension. American journal of hypertension. 2021;34:15\u201327.","journal-title":"American journal of hypertension"},{"key":"1998_CR15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271\u2013305.","journal-title":"Handb Exp Pharmacol"},{"key":"1998_CR16","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932\u201340.","journal-title":"J Biol Chem"},{"key":"1998_CR17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA Mcdonagh","year":"2021","unstructured":"Mcdonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1998_CR18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"1998_CR19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1998_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, Mcmurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"1998_CR21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152\u201361.","journal-title":"Eur Heart J"},{"key":"1998_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543\u201351.","journal-title":"N Engl J Med"},{"key":"1998_CR23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpdd.855","volume":"10","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Kawaguchi A. Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10:353\u201365.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2171\u20132183","key":"1998_CR24","volume":"42","author":"T Nakamura","year":"2020","unstructured":"Nakamura T, Shimizu H, Kawaguchi A. Drug-drug interactions of the nonsteroidal mineralocorticoid receptor antagonist apararenone with midazolam, warfarin, and digoxin: a Phase 1 studies in healthy volunteers. Clin Ther. 2020;42(2171\u20132183): e2174.","journal-title":"Clin Ther"},{"key":"1998_CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada T, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol. 2021;25:120\u201330.","journal-title":"Clin Exp Nephrol"},{"key":"1998_CR26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","volume":"13","author":"K Bamberg","year":"2018","unstructured":"Bamberg K, Johansson U, Edman K, et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One. 2018;13: e0193380.","journal-title":"PLoS One"},{"key":"1998_CR27","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.13562","volume":"84","author":"F Erlandsson","year":"2018","unstructured":"Erlandsson F, Albayaty M, Chialda L, et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. Br J Clin Pharmacol. 2018;84:1486\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"1998_CR28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cts.12705","volume":"13","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Kragh AM, Hartleib-Geschwindner J, et al. Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase i multiple ascending dose study. Clin Transl Sci. 2020;13:275\u201383.","journal-title":"Clin Transl Sci"},{"key":"1998_CR29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"1998_CR30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, et al. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358:548\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"1998_CR31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"1998_CR32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H, et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542\u201351.","journal-title":"J Hum Hypertens"},{"key":"1998_CR33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","volume":"44","author":"S Ito","year":"2021","unstructured":"Ito S, Itoh H, Rakugi H, et al. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens Res. 2021;44:489\u201397.","journal-title":"Hypertens Res"},{"key":"1998_CR34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, et al. Double-blind randomized Phase 3 study comparing esaxerenone (CS-3150) and Eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"1998_CR35","doi-asserted-by":"publisher","unstructured":"Chow CP, Liu JR, Tan XJ, et al. Pharmacological profile of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal disease. J Drug Res Dev. 2017;3(2). https:\/\/doi.org\/10.16966\/2470-1009.137.","DOI":"10.16966\/2470-1009.137"},{"key":"1998_CR36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","volume":"76","author":"G Bakris","year":"2020","unstructured":"Bakris G, Yang YF, Pitt B. Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial. Hypertension. 2020;76:144\u20139.","journal-title":"Hypertension"},{"key":"1998_CR37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L Barfacker","year":"2012","unstructured":"Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385\u2013403.","journal-title":"ChemMedChem"},{"key":"1998_CR38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","volume":"14","author":"B Pitt","year":"2012","unstructured":"Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668\u201375.","journal-title":"Eur J Heart Fail"},{"key":"1998_CR39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71:599\u2013608.","journal-title":"Hypertension"},{"key":"1998_CR40","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1998_CR41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","volume":"78","author":"G Bakris","year":"2021","unstructured":"Bakris G, Pergola PE, Delgado B, et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study. Hypertension. 2021;78:74\u201381.","journal-title":"Hypertension"},{"key":"1998_CR42","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/ajh\/hpad066","volume":"36","author":"GL Bakris","year":"2023","unstructured":"Bakris GL, Yang YF, Mccabe JM, et al. Efficacy and safety of ocedurenone: subgroup analysis of the BLOCK-CKD study. Am J Hypertens. 2023;36:612\u20138.","journal-title":"Am J Hypertens"},{"key":"1998_CR43","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"1998_CR44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50:333\u201344.","journal-title":"Am J Nephrol"},{"key":"1998_CR45","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"\u2022 Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329. This is the first RCT with hard clinical endpoints (FIDELIO-DKD) investigating the non-steroidal MRA finerenone in patients with diabetic kidney disease.","journal-title":"N Engl J Med"},{"key":"1998_CR46","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, Mcmurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"1998_CR47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50:345\u201356.","journal-title":"Am J Nephrol"},{"key":"1998_CR48","doi-asserted-by":"crossref","unstructured":"\u2022 Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.\u00a0This is the second RCT with hard clinical endpoints (FIGARO_DKD) investigating the non-steroidal MRA finerenone in patients with diabetic kidney disease.","DOI":"10.1056\/NEJMoa2110956"},{"key":"1998_CR49","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"key":"1998_CR50","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37:2105\u201314.","journal-title":"Eur Heart J"},{"key":"1998_CR51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145:437\u201347.","journal-title":"Circulation"},{"key":"1998_CR52","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022;24:996\u20131005.","journal-title":"Eur J Heart Fail"},{"key":"1998_CR53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-023-01899-0","volume":"22","author":"U Kintscher","year":"2023","unstructured":"Kintscher U, Edelmann F. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023;22:162.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01998-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-023-01998-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01998-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:46:51Z","timestamp":1706183211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-023-01998-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1998"],"URL":"https:\/\/doi.org\/10.1007\/s11886-023-01998-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"8 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"UK received research grants and honoraria (speaker\/advisory board) from BAYER AG, and received honoraria (speaker\/advisory board) from Amarin, Berlin Chemie, BMS, Boehringer Ingelheim, Novartis, Oviva, Roche, Sanofi, and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}